112 related articles for article (PubMed ID: 38215770)
41. Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial.
de Jonge NA; Sikkens JJ; Zweegman S; Beeker A; Ypma P; Herbers AH; Vasmel W; de Kreuk A; Coenen JLLM; Lissenberg-Witte B; Kramer MHH; van Agtmael MA; Janssen JJWM
Lancet Haematol; 2022 Aug; 9(8):e563-e572. PubMed ID: 35691326
[TBL] [Abstract][Full Text] [Related]
42. Elaboration of a consensual definition of de-escalation allowing a ranking of β-lactams.
Weiss E; Zahar JR; Lesprit P; Ruppe E; Leone M; Chastre J; Lucet JC; Paugam-Burtz C; Brun-Buisson C; Timsit JF;
Clin Microbiol Infect; 2015 Jul; 21(7):649.e1-10. PubMed ID: 25882363
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
[TBL] [Abstract][Full Text] [Related]
44. Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial.
Hill LF; Clements MN; Turner MA; Donà D; Lutsar I; Jacqz-Aigrain E; Heath PT; Roilides E; Rawcliffe L; Alonso-Diaz C; Baraldi E; Dotta A; Ilmoja ML; Mahaveer A; Metsvaht T; Mitsiakos G; Papaevangelou V; Sarafidis K; Walker AS; Sharland M;
Lancet Child Adolesc Health; 2022 Jan; 6(1):49-59. PubMed ID: 34843669
[TBL] [Abstract][Full Text] [Related]
45. Use of Fluoroquinolones or Sulfamethoxazole-Trimethoprim Compared to Β-Lactams for Oral Step-Down Therapy in Hospitalized Patients With Uncomplicated Enterobacterales Bacteremia.
Mack T; Hiles JJ; Wrin J; Desai A
Ann Pharmacother; 2023 Mar; 57(3):251-258. PubMed ID: 35758168
[TBL] [Abstract][Full Text] [Related]
46. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
[TBL] [Abstract][Full Text] [Related]
47. A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults.
Jimenez-Cruz F; Jasovich A; Cajigas J; Jiang Q; Imbeault D; Woods GL; Gesser RM;
Urology; 2002 Jul; 60(1):16-22. PubMed ID: 12100914
[TBL] [Abstract][Full Text] [Related]
48. Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial.
Tong SYC; Lye DC; Yahav D; Sud A; Robinson JO; Nelson J; Archuleta S; Roberts MA; Cass A; Paterson DL; Foo H; Paul M; Guy SD; Tramontana AR; Walls GB; McBride S; Bak N; Ghosh N; Rogers BA; Ralph AP; Davies J; Ferguson PE; Dotel R; McKew GL; Gray TJ; Holmes NE; Smith S; Warner MS; Kalimuddin S; Young BE; Runnegar N; Andresen DN; Anagnostou NA; Johnson SA; Chatfield MD; Cheng AC; Fowler VG; Howden BP; Meagher N; Price DJ; van Hal SJ; O'Sullivan MVN; Davis JS;
JAMA; 2020 Feb; 323(6):527-537. PubMed ID: 32044943
[TBL] [Abstract][Full Text] [Related]
49. Introducing the Escalation Antibiogram: A Simple Tool to Inform Changes in Empiric Antimicrobials in the Nonresponding Patient.
Teitelbaum D; Elligsen M; Katz K; Lam PW; Lo J; MacFadden D; Vermeiren C; Daneman N
Clin Infect Dis; 2022 Nov; 75(10):1763-1771. PubMed ID: 35380628
[TBL] [Abstract][Full Text] [Related]
50. Oral beta-lactam step down in bacteremic E. coli urinary tract infections.
Saad S; Mina N; Lee C; Afra K
BMC Infect Dis; 2020 Oct; 20(1):785. PubMed ID: 33087051
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
Maggio A; Kattamis A; Felisi M; Reggiardo G; El-Beshlawy A; Bejaoui M; Sherief L; Christou S; Cosmi C; Della Pasqua O; Del Vecchio GC; Filosa A; Cuccia L; Hassab H; Kreka M; Origa R; Putti MC; Spino M; Telfer P; Tempesta B; Vitrano A; Tsang YC; Zaka A; Tricta F; Bonifazi D; Ceci A
Lancet Haematol; 2020 Jun; 7(6):e469-e478. PubMed ID: 32470438
[TBL] [Abstract][Full Text] [Related]
52. A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia.
Vetter N; Cambronero-Hernandez E; Rohlf J; Simon S; Carides A; Oliveria T; Isaacs R;
Clin Ther; 2002 Nov; 24(11):1770-85. PubMed ID: 12501873
[TBL] [Abstract][Full Text] [Related]
53. Amoxicillin duration and dose for community-acquired pneumonia in children: the CAP-IT factorial non-inferiority RCT.
Barratt S; Bielicki JA; Dunn D; Faust SN; Finn A; Harper L; Jackson P; Lyttle MD; Powell CV; Rogers L; Roland D; Stöhr W; Sturgeon K; Vitale E; Wan M; Gibb DM; Sharland M
Health Technol Assess; 2021 Nov; 25(60):1-72. PubMed ID: 34738518
[TBL] [Abstract][Full Text] [Related]
54. Comparative efficacy and safety of antipseudomonal β-lactams for pediatric febrile neutropenia: A systematic review and Bayesian network meta-analysis.
Tan X; Li Y; Xi J; Guo S; Su H; Chen X; Liang X
Medicine (Baltimore); 2021 Dec; 100(50):e27266. PubMed ID: 34918626
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).
Kaye KS; Shorr AF; Wunderink RG; Du B; Poirier GE; Rana K; Miller A; Lewis D; O'Donnell J; Chen L; Reinhart H; Srinivasan S; Isaacs R; Altarac D
Lancet Infect Dis; 2023 Sep; 23(9):1072-1084. PubMed ID: 37182534
[TBL] [Abstract][Full Text] [Related]
56. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy.
Wells WG; Woods GL; Jiang Q; Gesser RM
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii67-74. PubMed ID: 15150185
[TBL] [Abstract][Full Text] [Related]
57. Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections: A Randomized Clinical Trial.
Sojo-Dorado J; López-Hernández I; Rosso-Fernandez C; Morales IM; Palacios-Baena ZR; Hernández-Torres A; Merino de Lucas E; Escolà-Vergé L; Bereciartua E; García-Vázquez E; Pintado V; Boix-Palop L; Natera-Kindelán C; Sorlí L; Borrell N; Giner-Oncina L; Amador-Prous C; Shaw E; Jover-Saenz A; Molina J; Martínez-Alvarez RM; Dueñas CJ; Calvo-Montes J; Silva JT; Cárdenes MA; Lecuona M; Pomar V; Valiente de Santis L; Yagüe-Guirao G; Lobo-Acosta MA; Merino-Bohórquez V; Pascual A; Rodríguez-Baño J;
JAMA Netw Open; 2022 Jan; 5(1):e2137277. PubMed ID: 35024838
[TBL] [Abstract][Full Text] [Related]
58. Duration of Exposure to Antipseudomonal β-Lactam Antibiotics in the Critically Ill and Development of New Resistance.
Teshome BF; Vouri SM; Hampton N; Kollef MH; Micek ST
Pharmacotherapy; 2019 Mar; 39(3):261-270. PubMed ID: 30506852
[TBL] [Abstract][Full Text] [Related]
59. Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-inferiority trials.
Chen MJ; Chen PY; Fang YJ; Bair MJ; Chen CC; Chen CC; Yang TH; Lee JY; Yu CC; Kuo CC; Chiu MC; Chou CK; Chen CY; Hu WH; Tsai MH; Hsu YC; Shun CT; Luo JC; Lin JT; El-Omar EM; Wu MS; Liou JM;
Lancet Gastroenterol Hepatol; 2023 Jul; 8(7):623-634. PubMed ID: 37178702
[TBL] [Abstract][Full Text] [Related]
60. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.
Piccart M; van 't Veer LJ; Poncet C; Lopes Cardozo JMN; Delaloge S; Pierga JY; Vuylsteke P; Brain E; Vrijaldenhoven S; Neijenhuis PA; Causeret S; Smilde TJ; Viale G; Glas AM; Delorenzi M; Sotiriou C; Rubio IT; Kümmel S; Zoppoli G; Thompson AM; Matos E; Zaman K; Hilbers F; Fumagalli D; Ravdin P; Knox S; Tryfonidis K; Peric A; Meulemans B; Bogaerts J; Cardoso F; Rutgers EJT
Lancet Oncol; 2021 Apr; 22(4):476-488. PubMed ID: 33721561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
